在体外，重组可溶性CD4可阻断HIV感染。

HIV infection is blocked in vitro by recombinant soluble CD4.

作者信息

Fisher R A, Bertonis J M, Meier W, Johnson V A, Costopoulos D S, Liu T, Tizard R, Walker B D, Hirsch M S, Schooley R T

机构信息

Biogen Research Corporation, Cambridge, Massachusetts 02142.

出版信息

Nature. 1988 Jan 7;331(6151):76-8. doi: 10.1038/331076a0.

DOI:10.1038/331076a0

PMID:2829022

Abstract

The T-cell surface glycoprotein, CD4 (T4), acts as the cellular receptor for human immunodeficiency virus, type 1 (HIV-1), the first member of the family of viruses that cause acquired immunodeficiency syndrome. HIV recognition of CD4 is probably mediated through the virus envelope glycoprotein (gp120) as shown by co-immunoprecipitation of CD4 and gp120 (ref.5) and by experiments using recombinant gp120 as a binding probe. Here we demonstrate that recombinant soluble CD4(rsT4) purified from the conditioned medium of a stably transfected Chinese hamster ovary cell line is a potent inhibitor of both virus replication and virus-induced cell fusion (syncytium formation). These results suggest that rsT4 is sufficient to bind HIV, and that it represents a potential anti-viral therapy for HIV infection.

摘要

T细胞表面糖蛋白CD4（T4）是人类免疫缺陷病毒1型（HIV-1）的细胞受体，HIV-1是导致获得性免疫缺陷综合征的病毒家族中的首个成员。如CD4与gp120的共免疫沉淀（参考文献5）以及使用重组gp120作为结合探针的实验所示，HIV对CD4的识别可能是通过病毒包膜糖蛋白（gp120）介导的。在此，我们证明从稳定转染的中国仓鼠卵巢细胞系的条件培养基中纯化得到的重组可溶性CD4（rsT4）是病毒复制和病毒诱导的细胞融合（合胞体形成）的有效抑制剂。这些结果表明，rsT4足以结合HIV，并且它代表了一种针对HIV感染的潜在抗病毒疗法。